Brian Gibler / Friday, December 4, 2020 / Categories: Fibrinolytic Therapy, Care Team, EM, Hosp Med, Neuro, Neurophys, Neurosurg, Stroke Team, Diagnosis, IS, Controversies, EBM, IV Rx, Standard Care, Treatments, Types of Content, Video Article, Video Article IV tPA for Acute Strokes in Patients with COVID - What Does the Limited Evidence Mean? The incidence of acute stroke in COVID-19 patients occurs at a rate that is at least 7 times greater than the general population. Controversy about the safety and efficacy of IV-tPA remains. Dr. Matthew Smith, a fellow in neurocritical care and endovascular neurointervention presents key data and recommendations regarding the treatment of acute stroke in patients with COVID. Addressing the initial data from the early days of the pandemic and the newer data released, Dr. Smith guides the learner through an assessment of the efficacy and safety of IV-rtPA in the treatment of acute strokes in the era of COVID. Previous Article The Good, the Bad and the Ugly of the NIHSS: Time for a Change? Next Article Why Is the Extended Window Controversial and What Happened With the FDA? Print 11083 Rate this article: No rating Please login or register to post comments.